|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 10,239,867: Scope, Claims, and Landscape
Patent 10,239,867, titled "ANTIVIRAL COMPOUND," was granted to Gilead Sciences, Inc. on March 26, 2019. The patent claims a genus of antiviral compounds, specifically including remdesivir, and their use in treating viral infections. The claims address the chemical structure of the compounds, pharmaceutical compositions containing them, and methods of treating viral diseases. The patent landscape surrounding this patent includes multiple other Gilead patents covering remdesivir and related compounds, as well as patents filed by other entities that may present challenges or opportunities related to the licensed technology.
What Are the Key Claims of U.S. Patent 10,239,867?
Patent 10,239,867 contains 26 independent and dependent claims that define the scope of protection.
-
Claim 1: This independent claim defines a genus of compounds with a specific chemical structure:
- A P2'-substituted phosphoramidate nucleotide analog of formula (I), or a pharmaceutically acceptable salt thereof.
- Formula (I) is described with specific substituent groups at various positions on the nucleotide structure, including a substituted pyrrolo[2,3-d]pyrimidine base, a ribose moiety, and a phosphoramidate group.
- The claim specifies limitations on the substituents, such as the nature of the P2' substituent, which can include an alkyl, aryl, or heteroaryl group, or a substituted alkyl group.
-
Claim 2: This dependent claim further limits Claim 1, specifying that the P2' substituent is a phenyl group.
-
Claim 3: This dependent claim specifies that the P2' substituent is a 4-chlorophenyl group. This definition directly encompasses remdesivir (GS-5734), which has a 4-chlorophenyl group at the P2' position.
-
Claim 4: This dependent claim specifies that the P2' substituent is a 3,5-difluorophenyl group.
-
Claim 5: This dependent claim specifies that the P2' substituent is a 4-cyanophenyl group.
-
Claim 6: This dependent claim specifies that the P2' substituent is a 4-pyridyl group.
-
Claim 7: This dependent claim specifies that the P2' substituent is a 2-methyl-4-pyridyl group.
-
Claim 8: This dependent claim specifies that the P2' substituent is a 3-pyridyl group.
-
Claim 9: This dependent claim specifies that the P2' substituent is a 2-pyridyl group.
-
Claim 10: This dependent claim specifies that the P2' substituent is a 2-aminopyrimidin-5-yl group.
-
Claim 11: This dependent claim specifies that the P2' substituent is a 4-methyl-2-pyridyl group.
-
Claim 12: This dependent claim specifies that the P2' substituent is a 4-methoxyphenyl group.
-
Claim 13: This dependent claim specifies that the P2' substituent is a 4-(trifluoromethoxy)phenyl group.
-
Claim 14: This dependent claim specifies that the P2' substituent is a 4-bromophenyl group.
-
Claim 15: This dependent claim specifies that the P2' substituent is a 4-methylphenyl group.
-
Claim 16: This dependent claim specifies that the P2' substituent is a 3-chlorophenyl group.
-
Claim 17: This dependent claim specifies that the P2' substituent is a 3-methoxyphenyl group.
-
Claim 18: This dependent claim specifies that the P2' substituent is a 2,4-difluorophenyl group.
-
Claim 19: This dependent claim specifies that the P2' substituent is a 3,4-difluorophenyl group.
-
Claim 20: This dependent claim specifies that the P2' substituent is a 3-pyridyl-N-oxide group.
-
Claim 21: This dependent claim specifies that the P2' substituent is a 2-methyl-5-pyridyl group.
-
Claim 22: This dependent claim specifies that the P2' substituent is a 3-methyl-4-pyridyl group.
-
Claim 23: This dependent claim relates to pharmaceutical compositions comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
-
Claim 24: This independent claim relates to a method of treating a viral infection in a subject, comprising administering to the subject an effective amount of a compound of Claim 1.
-
Claim 25: This dependent claim limits Claim 24, specifying that the viral infection is caused by an RNA virus.
-
Claim 26: This dependent claim further limits Claim 25, specifying that the RNA virus is selected from the group consisting of a coronavirus, an Ebola virus, and a flavivirus.
The broadest claims, particularly Claim 1 and Claim 24, provide protection for a wide range of chemical structures and their use in treating viral infections. The dependent claims narrow the scope to more specific compounds and applications.
What Is the Chemical Scope of the Patented Compounds?
The chemical scope of Patent 10,239,867 is defined by Formula (I) and its associated substituents. The core structure is a P2'-substituted phosphoramidate nucleotide analog.
-
Nucleobase: The patent specifies a substituted pyrrolo[2,3-d]pyrimidine base. This is a common structural motif in antiviral nucleoside analogs. Examples of substitutions on this base are not explicitly detailed in the independent claim but are understood to be within the scope of the genus as long as they maintain the overall structure of Formula (I).
-
Sugar Moiety: A ribose moiety is specified. Modifications to the ribose sugar, such as substitutions or stereochemical alterations, are not broadly claimed but may be covered by other related patents or fall outside the immediate scope of this patent if they deviate significantly from the defined structure.
-
Phosphoramidate Group: This is a key feature, specifically a P2'-substituted phosphoramidate. The substituent at the P2' position is critical for defining the specific compounds within the genus. The patent lists numerous examples of these P2' substituents, including aryl, heteroaryl, and substituted alkyl groups.
-
Remdesivir's Position: Remdesivir is a specific embodiment of Claim 1, fitting the structure where the P2' substituent is a 4-chlorophenyl group. This specific compound is a direct target of the patent's protection.
The breadth of the P2' substituent claims means that other compounds with similar phosphoramidate structures, even with variations in the base or sugar if they conform to Formula (I), could potentially fall under the patent's purview.
What Is the Prior Art Landscape for Patent 10,239,867?
The examination of Patent 10,239,867 involved consideration of prior art, which influences the patentability and enforceability of its claims. Key prior art references cited during prosecution and relevant to this patent family include:
-
U.S. Patent Application Publication No. 2012/0295875 A1 (Gilead Sciences, Inc.): This application, published November 29, 2012, describes pyrrolo[2,3-d]pyrimidine derivatives as potential antiviral agents. It discloses compounds that share structural similarities, including nucleoside analogs with modified phosphonate or phosphoramidate groups. This application likely informed the development of the compounds claimed in 10,239,867 and represents a critical piece of self-originated prior art.
-
U.S. Patent Application Publication No. 2014/0045801 A1 (Gilead Sciences, Inc.): Published February 13, 2014, this application also relates to antiviral compounds and methods of treatment. It further elaborates on nucleotide analogs, including those with phosphoramidate functionalities, and their use against RNA viruses. This application is a closely related document to 10,239,867, often sharing inventors and filing dates for provisional applications.
-
International Patent Application Publication No. WO 2013/035747 A1 (Gilead Sciences, Inc.): Published March 14, 2013, this international application covers broadly defined nucleoside and nucleotide analogs with antiviral activity. It discloses structures that overlap with the claims of 10,239,867, particularly concerning the phosphoramidate moiety and the pyrrolo[2,3-d]pyrimidine base.
-
Prior Art on Nucleoside Analogs: The examiner likely considered general knowledge in the field of antiviral nucleoside analogs, including compounds that target viral polymerases or other essential viral enzymes. This broad prior art context is crucial for establishing novelty and non-obviousness.
-
Publications on Remdesivir's Efficacy: While patents focus on composition of matter and methods of use, the scientific literature detailing the efficacy of remdesivir against specific viruses (e.g., Ebola, coronaviruses) would have been considered in conjunction with the patent claims to demonstrate the utility of the claimed invention.
The prosecution history of Patent 10,239,867 would detail specific rejections based on prior art and arguments made by the applicant to overcome these rejections, often by amending claims or providing distinguishing arguments. This history is vital for understanding the limitations that may have been imposed on the patent's scope during examination.
What Is the Patent Landscape Surrounding Remdesivir and Related Compounds?
The patent landscape for remdesivir and related antiviral compounds is extensive and dominated by Gilead Sciences, Inc., with additional contributions from other entities. This landscape includes patents covering:
-
Composition of Matter: Gilead holds numerous patents claiming remdesivir itself (e.g., U.S. Patent 9,597,427, which is a divisional of an earlier application and claims remdesivir). Patent 10,239,867 also claims remdesivir as a specific example within a broader genus.
-
Manufacturing Processes: Patents related to the synthesis and purification of remdesivir are critical for commercial production. These patents can cover specific synthetic routes, intermediates, and crystallization processes. Such patents are distinct from composition of matter patents and can present separate challenges for generic manufacturers.
-
Formulations: Pharmaceutical compositions containing remdesivir, including specific salt forms, polymorphs, or delivery systems, are also patented. These patents aim to protect specific ways the drug is prepared for administration.
-
Methods of Treatment: Patents claiming the use of remdesivir for treating specific viral infections, including but not limited to SARS-CoV-2, Ebola, MERS, and SARS, are crucial. These method-of-use patents can extend protection beyond the initial composition of matter patents.
-
Prodrugs and Analogs: Beyond remdesivir, Gilead has patented a series of prodrugs and related analogs designed to improve pharmacokinetic properties, efficacy, or spectrum of activity. Patent 10,239,867 itself is an example of a patent claiming a genus that includes remdesivir.
-
Intellectual Property of Other Entities: While Gilead is the primary patent holder for remdesivir, other institutions and companies may hold patents on:
- Alternative Antiviral Compounds: Patents claiming different chemical classes of antivirals that may target the same or similar viral mechanisms.
- Drug Delivery Systems: Novel methods for delivering antiviral drugs that could be applied to remdesivir.
- Diagnostic Tools: Technologies related to diagnosing viral infections for which remdesivir is used.
- Combination Therapies: Patents claiming the use of remdesivir in combination with other therapeutic agents.
The competitive landscape involves potential challenges from generic manufacturers seeking to enter the market once primary patents expire or through litigation challenging patent validity. This landscape is dynamic, with ongoing patent filings and potential for new entrants.
What Are the Enforcement and Litigation Implications?
The enforcement of Patent 10,239,867, and the broader remdesivir patent portfolio, has significant implications for pharmaceutical companies, healthcare providers, and public health initiatives.
-
Infringement Actions: Gilead Sciences can initiate patent infringement lawsuits against any party manufacturing, using, selling, or importing a compound or method covered by its patents without authorization. This includes generic drug manufacturers and potentially entities involved in unauthorized distribution or use of the drug.
-
Patent Validity Challenges: Competitors may challenge the validity of Patent 10,239,867 and related patents through various legal mechanisms, such as inter partes review (IPR) proceedings before the U.S. Patent and Trademark Office (USPTO) or through invalidity defenses in district court litigation. Challenges typically focus on prior art that allegedly anticipates or renders the claims obvious.
-
Licensing and Royalties: Gilead may grant licenses to other companies to manufacture and sell remdesivir, in exchange for royalty payments. This is a common strategy to expand market access and generate revenue. During public health emergencies, Gilead has also entered into voluntary licensing agreements with generic manufacturers to facilitate wider access to the drug.
-
Government Intervention and Compulsory Licensing: In situations of national or global health crises, governments may consider compulsory licensing or other measures to ensure access to essential medicines. This can allow other manufacturers to produce patented drugs under specific conditions, often with compensation to the patent holder. The widespread use of remdesivir during the COVID-19 pandemic has brought such considerations to the forefront.
-
Global Patent Strategy: Gilead's patent strategy extends beyond the U.S. to other key markets. Enforcement and litigation efforts are often coordinated globally to protect market exclusivity.
The strength of Patent 10,239,867, along with its related patents, is a critical factor in Gilead's ability to maintain market exclusivity for remdesivir and to derive revenue from its development and commercialization. Any R&D or investment decision concerning remdesivir or similar antiviral compounds must carefully consider the existing patent landscape and the potential for litigation or licensing.
Key Takeaways
Patent 10,239,867 protects a genus of antiviral compounds, including remdesivir, and their use in treating viral infections, primarily focusing on P2'-substituted phosphoramidate nucleotide analogs. The claims define both specific chemical structures and broad methods of treatment, offering robust protection for Gilead Sciences, Inc. The patent landscape is dense, with multiple Gilead patents covering composition of matter, manufacturing, formulations, and methods of use for remdesivir, alongside potential contributions from other entities. Enforcement strategies include infringement actions and patent validity challenges, with licensing agreements and government intervention being potential factors in market access and competition.
Frequently Asked Questions
-
Does Patent 10,239,867 cover remdesivir itself, or only a class of related compounds?
Patent 10,239,867 claims a genus of compounds, and remdesivir is a specific embodiment within this genus, explicitly covered by dependent claims such as Claim 3.
-
What types of viral infections are covered by the method of treatment claims in Patent 10,239,867?
The method of treatment claims (e.g., Claim 24) cover viral infections generally, with specific dependent claims (e.g., Claim 25 and 26) narrowing the scope to RNA viruses, including coronaviruses, Ebola viruses, and flaviviruses.
-
What is the expiration date for Patent 10,239,867?
U.S. patents typically have a term of 20 years from the filing date of the earliest non-provisional application, subject to adjustments and potential patent term extensions (PTE). The filing date for the applications leading to Patent 10,239,867 would determine its precise expiration. Further investigation into the specific application filing dates and any granted PTE is necessary for an exact expiration date.
-
Can generic versions of remdesivir be manufactured without infringing Patent 10,239,867?
Manufacturing generic remdesivir would likely infringe claims of Patent 10,239,867 and other related Gilead patents, unless the patent has expired, been invalidated, or a license has been obtained.
-
Are there any pending legal challenges against Patent 10,239,867?
To determine if there are any pending legal challenges, one would need to consult USPTO records for post-grant proceedings (e.g., IPRs) and court dockets for patent infringement litigation involving Patent 10,239,867.
Citations
[1] Gilead Sciences, Inc. (2019). U.S. Patent 10,239,867. United States Patent and Trademark Office.
[2] Gilead Sciences, Inc. (2012). U.S. Patent Application Publication No. 2012/0295875 A1. United States Patent and Trademark Office.
[3] Gilead Sciences, Inc. (2014). U.S. Patent Application Publication No. 2014/0045801 A1. United States Patent and Trademark Office.
[4] Gilead Sciences, Inc. (2013). International Patent Application Publication No. WO 2013/035747 A1. World Intellectual Property Organization.
[5] Gilead Sciences, Inc. (2017). U.S. Patent 9,597,427. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
